Leveraging Generative AI for Drug Discovery and Molecular Design in Biomedical Research

Ghan Twan Eng,

Authors

Ghan Twan Eng, Nigeria Author

Keywords:

Generative AI, Drug Discovery, Molecular Design, Deep Learning, Biomedical Research

Abstract

Generative Artificial Intelligence (AI) is revolutionizing biomedical research, particularly in drug discovery and molecular design. By enhancing predictive modeling, structure-based drug generation, and optimization, generative AI enables faster identification of novel compounds and therapeutic candidates. This paper explores the advancements in generative AI applications, reviews recent literature, and provides insights into its transformative impact on biomedical research. Case studies and examples highlight its utility and future prospects.

References

Gómez-Bombarelli, Rafael, et al. “Automatic Chemical Design Using a Data-Driven Generative Model.” ACS Central Science, vol. 4, no. 2, 2018, pp. 268–276.

De Cao, Nicola, and Thomas Kipf. “MolGAN: An Implicit Generative Model for Small Molecular Graphs.” arXiv, 2018, arXiv:1805.11973.

Paramasivan, A. (2023). Transforming healthcare supply chains: AI for efficient drug distribution and inventory management. International Journal on Science and Technology (IJSAT), 14(3), 1–15.

Zhavoronkov, Alex, et al. “Deep Learning Enables Rapid Identification of Potent DDR1 Kinase Inhibitors.” Nature Biotechnology, vol. 37, no. 9, 2019, pp. 1038–1040.

Jumper, John, et al. “Highly Accurate Protein Structure Prediction with AlphaFold.” Nature, vol. 596, no. 7873, 2021, pp. 583–589.

Paul, Steven M., et al. “How to Improve R&D Productivity: The Pharmaceutical Industry’s Grand Challenge.” Nature Reviews Drug Discovery, vol. 9, no. 3, 2010, pp. 203–214.

Sanchez-Lengeling, Benjamin, and Alán Aspuru-Guzik. “Inverse Molecular Design Using Machine Learning: Generative Models for Matter Engineering.” Science, vol. 361, no. 6400, 2018, pp. 360–365.

Paramasivan, A. (2021). Smart health systems: Leveraging machine learning to enhance hospital workflow and patient outcomes. Journal of Scientific and Engineering Research, 8(6), 211–219.

Zhavoronkov, Alex, et al. “Artificial Intelligence in Drug Discovery: A Comprehensive Review.” Molecular Pharmaceutics, vol. 17, no. 3, 2020, pp. 1078–1093.

Polykovskiy, Daniil, et al. “Molecular Sets (MOSES): A Benchmarking Platform for Molecular Generation Models.” arXiv, 2018, arXiv:1811.12823.

Ragoza, Matthew, et al. “Protein–Ligand Scoring with Convolutional Neural Networks.” Journal of Chemical Information and Modeling, vol. 57, no. 4, 2017, pp. 942–957.

Paramasivan, A. (2021). Unleashing AI: How self-learning algorithms are shaping the future of card security. Journal of Scientific and Engineering Research, 8(10), 231–243.

Stokes, Jonathan M., et al. “A Deep Learning Approach to Antibiotic Discovery.” Cell, vol. 180, no. 4, 2020, pp. 688–702.e13.

Merk, Dominik, et al. “De Novo Design of Bioactive Small Molecules by Artificial Intelligence.” Molecular Informatics, vol. 37, no. 1–2, 2018, p. 1700153.

Gawehn, Erik, Johannes A. Hiss, and Gisbert Schneider. “Deep Learning in Drug Discovery.” Molecular Informatics, vol. 35, no. 1, 2016, pp. 3–14.

Segler, Marwin H., Mike Preuss, and Mark P. Waller. “Planning Chemical Syntheses with Deep Neural Networks and Symbolic AI.” Nature, vol. 555, no. 7698, 2018, pp. 604–610.

Xiong, Ziqi, et al. “Pushing the Boundaries of Molecular Representation for Drug Discovery with Deep Learning.” Nature Communications, vol. 12, no. 1, 2021, pp. 1–11.

Kim, Sunghwan, et al. “PubChem Substance and Compound Databases.” Nucleic Acids Research, vol. 44, no. D1, 2016, pp. D1202–D1213.